Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nuvation Bio, Inc.
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
June 29, 2026
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
June 26, 2026
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
June 25, 2026
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
May 27, 2026
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
May 27, 2026
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
May 21, 2026
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
May 6, 2026
Nuvation Bio to Participate in Upcoming Investor Conferences
May 6, 2026
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
May 5, 2026
1
2
Next Page
→